Abstract Search

ea0099oc7.3 | Oral Communications 7: Endocrine-related Cancer | ECE2024

How close we are to optimise the assessment of SSTR status in NEN with a radiolabelled SSTR antagonist-final results of the TECANT clinical trial: Novel 99mTc-labelled somatostatin antagonists in the diagnostic algorithm of neuroendocrine neoplasms

Hubalewska-Dydejczyk Alicja , Ležaić Luka , Decristoforo Clemens , Mikolajczak Renata , Virgolini Irene , Kolenc Petra , Suden Andrej , Simoncic Urban , Opalinska Marta , Trofimiuk-Muldner Malgorzata , Garnuszek Piotr , di Santo Gianpaolo , Novak Doroteja , Rangger Christine , Kroselj Marko , Skorkiewicz Konrad , Fani Melpomeni , Janota Barbara , Glowa Boguslaw , Sawicka Agnieszka

Introduction/Aim: Within the past two decades, the imaging and treatment of patients with neuroendocrine neoplasms (NEN) has been redefined by the successful introduction of radiolabelled somatostatin receptor (SSTR)-agonists targeting SSTR-subtype2 (SSTR2) overexpressed in NEN cells. Reliable assessment of the SSTR status of the primary focus/metastasis in different NEN locations is a cornerstone of NEN management and enables a personalised/precise therapeutic appr...

0 shares

Endocrine Abstracts

How close we are to optimise the assessment of SSTR status in NEN with a radiolabelled SSTR antagonist-final results of the TECANT clinical trial: Novel 99mTc-labelled somatostatin antagonists in the diagnostic algorithm of neuroendocrine neoplasms

BiosciAbstracts